UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 19, 2008
Medicis Pharmaceutical Corporation
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
0-18443
|
|
52-1574808 |
| |
|
|
|
|
| (State of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer |
|
|
|
|
|
Identification Number) |
8125 North Hayden Road
Scottsdale, Arizona 85258-2463
(Address of principal executive offices) (Zip Code)
(602) 808-8800
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
Item 8.01 Other Events.
On May 19, 2008, Medicis Pharmaceutical Corporation and Ipsen, S.A. issued a joint press
release announcing that the re-submission of the Biologics License Application for RELOXIN® had
been accepted by the U.S. Food and Drug Administration on May 16, 2008. A copy of the joint press
release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01 Exhibits.
(c) Exhibits
99.1 Press Release dated May 19, 2008